AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment

European Neuropsychopharmacology

Volumn 23, Issue 8, 2013, Pages 887-894

  Drago, Antonio ^b,d   Giegling, Ina ^a,d   Schäfer, Martin ^a,d,f   Hartmann, Annette M ^a,d   Friedl, Marion ^a,d   Konte, Bettina ^a,d   Möller, Hans Jürgen ^a,d   De Ronchi, Diana ^b,d   Stassen, Hans H ^c,d   Serretti, Alessandro ^b,d   Rujescu, Dan ^a,d,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^d UNIVERSITY OF COLOGNE   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Antipsychotic; Gene; Haloperidol; PANSS; Pharmacogenetics

Indexed keywords

HALOPERIDOL;

ACUTE PSYCHOSIS; ADULT; ARTICLE; BIPOLAR MANIA; CATATONIC SCHIZOPHRENIA; DRUG EFFICACY; FEMALE; GENE; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RESIDUAL SCHIZOPHRENIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIPSYCHOTIC; GENE; HALOPERIDOL; PANSS; PHARMACOGENETICS;

A KINASE ANCHOR PROTEINS; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CALCIUM CHANNELS; DRUG RESISTANCE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GERMANY; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; YOUNG ADULT;

EID: 84881659776     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.08.013     Document Type: Article

References (23)

1. Arranz M.J., Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use?. Schizophr. Bull. 2008, 34(6):1130-1144.
2. Arranz M.J., de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 2007, 12(8):707-747.
3. Berrettini W. Bipolar disorder and schizophrenia: convergent molecular data. Neuromol. Med. 2004, 5(1):109-117.
4. Cacabelos R., Hashimoto R., Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin. Neurosci. 2011, 65(1):3-19.
5. Gharabawi G.M., Bossie C.A., Lasser R.A., et al. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr. Res. 2005, 77(2-3):119-128.
6. Giegling I., Drago A., Schäfer M., et al. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J. Psychiatr. Res. 2010, 44(8):487-492.
7. Giegling I., Drago A., Schäfer M., et al. Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(1):74-77.
8. Ikeda M., Tomita Y., Mouri A., et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol. Psychiatry 2010, 67(3):263-269.
9. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
10. Knight J.C. Genetics and the general physician: insights, applications and future challenges. QJM 2009, 102(11):757-772.
11. Lavedan C., Licamele L., Volpi S., et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 2009, 14(8):804-819.
12. Lin P.-I., Mitchell B.D. Approaches for unraveling the joint genetic determinants of schizophrenia and bipolar disorder. Schizophr. Bull. 2008, 34(4):791-797.
13. Maheux J., Vuillier L., Mahfouz M., et al. Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain. Int. J. Neuropsychopharmacol. 2011, 1-13.
14. McClay J.L., Adkins D.E., Aberg K., et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 2011, 16(1):76-85.
15. Neyman S., Manahan-Vaughan D. Metabotropic glutamate receptor 1 (mGluR1) and 5 (mGluR5) regulate late phases of LTP and LTD in the hippocampal CA1 region in vitro. Eur. J. Neurosci. 2008, 27(6):1345-1352.
16. Ploski J.E., Pierre V.J., Smucny J., et al. The activity-regulated cytoskeletal-associated protein (Arc/Arg3.1) is required for memory consolidation of pavlovian fear conditioning in the lateral amygdala. J. Neurosci. 2008, 28(47):12383-12395.
17. Porcelli S., Drago A., Fabbri C., Serretti A. Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 2011 Aug 15;35(7):1532-43. Epub 2011 Mar 11. Review.
18. Rex C.S., Lin C.-Y., Kramár E.A., et al. Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J. Neurosci. 2007, 27(11):3017-3029.
19. Risselada A.J., Vehof J., Bruggeman R., et al. Association between the 1291-C/G polymorphism in the adrenergic α-2a receptor and the metabolic syndrome. J. Clin. Psychopharmacol. 2010, 30(6):667-671.
20. Sachs G.S., Thase M.E., Otto M.W., et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 2003, 53(11):1028-1042.
21. Saiz P.A., Susce M.T., Clark D.A., et al. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum. Psychopharmacol. 2008, 23(2):107-114.
22. Schäfer M., Rujescu D., Giegling I., et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am. J. Psychiatry 2001, 158(5):802-804.
23. Serretti A., Kato M., Kennedy J.L. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 2008, 8(2):90-100.